Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD)

Ya Efebera, A. S. Ruppert, Apollinaire Ngankeu, Sabrina L Garman, Prashanti Kumchala, Alan Howard, Sm Devine, Parthasarathy Ranganathan, Ramiro GarzonInternational Journal of Bone Marrow Research 2019 · DOI

TL;DR

This study investigated whether serum levels of microRNA-155 (miR-155) could serve as a reliable biomarker for acute graft-versus-host disease (aGVHD) following allogeneic stem cell transplantation. Despite previous findings suggesting miR-155 upregulation in aGVHD, this research found no significant difference in serum miR-155 levels between aGVHD patients and controls at the time of aGVHD onset, suggesting it may not be a suitable standalone biomarker.

What Problem Does This Paper Address?

Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a life-saving treatment for many blood cancers. However, a significant complication is acute graft-versus-host disease (aGVHD), where the donor's immune cells attack the recipient's body. aGVHD affects 30-50% of patients and is associated with high morbidity and mortality. Current treatments often involve broad immunosuppression, which can lead to opportunistic infections and may be ineffective in patients who are refractory to steroids. Therefore, there's a critical need for early and accurate biomarkers to detect aGVHD before clinical symptoms appear, allowing for timely intervention and potentially improving treatment outcomes and reducing toxicity. While some protein-based biomarkers have been identified, their limitations (e.g., need for high-affinity antibodies) highlight the potential of other molecules, such as cell-free nucleic acids like microRNAs.

Methods

The researchers aimed to validate previous findings on elevated circulating miR-155 in aGVHD. They analyzed serum samples from patients enrolled in the BMT CTN 0101 study, a randomized trial comparing fluconazole and voriconazole for fungal infection prevention post-alloHSCT. They collected samples from 98 patients at the time of aGVHD onset and matched them with controls who did not develop aGVHD (49 pairs).

Serum total RNA was extracted using a modified miRNeasy Serum/Plasma Kit. A synthetic microRNA spike-in control was added for normalization. Reverse transcription and quantitative real-time PCR (RT-qPCR) were performed using the Qiagen miScript PCR System to measure miR-155 expression. The expression levels were quantified as -Delta CT values, where higher values indicate higher expression. Statistical analysis included a paired t-test to compare -ACT values between aGVHD cases and controls, and conditional logistic regression was used to adjust for potential confounding variables.

Datasets

The study utilized serum samples from patients enrolled in the Blood and Marrow Transplant Clinical Trial Network (BMT CTN) 0101 study. This trial involved 98 patients who underwent allogeneic stem cell transplantation. Samples were collected at the time of aGVHD onset and matched with controls who did not develop aGVHD. The samples were obtained from the National Heart, Lung, and Blood Institute Biologic Specimen Repository (NHLBI Biorepository).

Key Insights and Ideas

  • miR-155's Role in aGVHD: Previous research suggested that miR-155 plays a role in aGVHD pathogenesis, leading to the hypothesis that its circulating levels might increase during the disease.
  • Discrepancy with Prior Studies: This study's finding of no significant difference in serum miR-155 levels at aGVHD onset contrasts with earlier reports that indicated upregulation. This highlights the complexity of biomarker discovery and the need for careful validation across different patient populations and study designs.
  • Potential Reasons for Discrepancy: The authors suggest several reasons for the differing results, including smaller sample sizes in previous studies, differences in patient populations (this study focused on hematologic malignancies), and potential degradation of RNA in stored samples collected between 2003-2006.
  • Limitations of Current Biomarkers: The paper underscores that while protein-based biomarkers exist, they have drawbacks. The search for RNA-based biomarkers like microRNAs is crucial for developing more comprehensive and accessible diagnostic tools.
  • Need for Serial Sampling: The study acknowledges a significant limitation: the lack of serial samples. This prevents the evaluation of miR-155 levels prior to aGVHD onset or tracking changes over time, which would be essential for establishing its prognostic value.

Key Results

  • A paired t-test showed that the average -ACT value for serum miR-155 expression was 0.29 units higher in aGVHD cases compared to matched controls (95% CI: -0.12 to 0.70).
  • This difference was not statistically significant (p = 0.16).
  • The corresponding relative fold change was 1.22 (95% CI: 0.92 to 1.63), which was also not significant.
  • When adjusting for donor source (a variable found to be significantly associated with aGVHD), the association between miR-155 and aGVHD remained non-significant (p=0.16).
  • The only clinical variable significantly associated with aGVHD in this cohort was donor source, with a higher proportion of cases receiving stem cells from peripheral blood compared to controls (84% vs. 61%, p=0.02).

Limitations and Future Work

The authors acknowledge several limitations:

  • Sample Size: While larger than some previous studies, the sample size is still considered relatively small.
  • Timing of Samples: Samples were collected at aGVHD onset, not serially, precluding the assessment of miR-155 as an early predictive or prognostic marker. The storage of samples for an extended period (2003-2006) also raises concerns about potential RNA degradation.
  • Limited Patient Population: The study focused on hematologic malignancies, which might differ from broader patient populations studied previously.

The authors emphasize the need for comprehensive studies with serial samples from a large number of patients, utilizing robust profiling methods, to identify reliable RNA or DNA circulating biomarkers for aGVHD.

Summary updated

BibTeX
@article{efebera2019serum,
  author = {YA Efebera and A. S. Ruppert and Apollinaire Ngankeu and Sabrina L Garman and Prashanti Kumchala and Alan Howard and SM Devine and Parthasarathy Ranganathan and Ramiro Garzon},
  title = {{Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD)}},
  journal = {International journal of bone marrow research.},
  year = {2019},
  doi = {10.29328/journal.ijbmr.1001007},
}
Figure